Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2016

Open Access 01-12-2016 | Research

Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression

Authors: Rui Bi, Xuxia Shen, Weiwei Zhang, Yufan Cheng, Zheng Feng, Xu Cai, Wentao Yang

Published in: Diagnostic Pathology | Issue 1/2016

Login to get access

Abstract

Background

Ovarian clear cell carcinoma (CCC) is an uncommon subtype of ovarian epithelial tumor. The prognostic significance of its clinicopathological parameters is discordant, with the exception of stage as the adverse prognostic factor. The present study aimed to evaluate the prognostic significance of its clinicopathological characteristics and the expression of IMP3 (Insulin-like growth factor-II mRNA-binding protein 3, IMP3 or IGF2BP3) in Chinese patients with primary pure CCC.

Methods

We collected clinicopathological data from 73 cases with a minimum of 5 years of follow-up and evaluated the expression of IMP3 by immunohistochemistry.

Results

In total, 49.3 % of the patients were in stage I. Advanced stages were closely related to poor prognosis of disease-free survival (DFS) and overall survival (OS) (P < 0.005). Patients with CCC coexisting with endometriosis tended to be younger and to have unilateral involvement but did not exhibit differences in prognosis compared with patients with CCC without endometriosis. Other histological features such as growth pattern, mitosis, and necrosis did not have prognostic significance. IMP3 was positive in 63 % of patients (46 of 73 cases); Thus, positive expression of IMP3 is an adverse prognostic marker in terms of OS (P = 0.012), even in stage I patients (P = 0.038).

Conclusions

The present study demonstrates that IMP3 expression is a prognostic marker, with the exception of stage. IMP3 represents a biomarker of unfavorable prognosis even in stage I patients.
Literature
1.
Anglesio MS, Carey MS, Kobel M, Mackay H, Huntsman DG. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol. 2011;121:407–15.CrossRefPubMed
2.
Han G, Gilks CB, Leung S, Ewanowich CA, Irving JA, Longacre TA, et al. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases. Am J Surg Pathol. 2008;32:955–64.CrossRefPubMed
3.
Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584–9.CrossRefPubMed
4.
del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol. 2012;126:481–90.CrossRefPubMed
5.
Lee YY, Kim TJ, Kim MJ, Kim HJ, Song T, Kim MK, et al. Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis. Gynecol Oncol. 2011;122:541–7.CrossRefPubMed
6.
Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008;109:370–6.CrossRefPubMed
7.
Yamamoto S, Tsuda H, Shimazaki H, Takano M, Yoshikawa T, Kuzuya K, et al. Histological grading of ovarian clear cell adenocarcinoma: proposal for a simple and reproducible grouping system based on tumor growth architecture. Int J Gynecol Pathol. 2012;31:116–24.CrossRefPubMed
8.
Jeng YM, Wang TH, Lu SH, Yuan RH, Hsu HC. Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma. Br J Surg. 2009;96:66–73.CrossRefPubMed
9.
Yuan RH, Wang CC, Chou CC, Chang KJ, Lee PH, Jeng YM. Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol. 2009;16:1711–9.CrossRefPubMed
10.
Schaeffer DF, Owen DR, Lim HJ, Buczkowski AK, Chung SW, Scudamore CH, et al. Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) overexpression in pancreatic ductal adenocarcinoma correlates with poor survival. BMC Cancer. 2010;10:59.PubMedCentralCrossRefPubMed
11.
Jeng YM, Chang CC, Hu FC, Chou HY, Kao HL, Wang TH, et al. RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma. Hepatology. 2008;48:1118–27.CrossRefPubMed
12.
Kobel M, Xu H, Bourne PA, Spaulding BO, Shih Ie M, Mao TL, et al. IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. Mod Pathol. 2009;22:469–75.CrossRefPubMed
13.
Fadare O, Liang SX, Crispens MA, Jones 3rd HW, Khabele D, Gwin K, et al. Expression of the oncofetal protein IGF2BP3 in endometrial clear cell carcinoma: assessment of frequency and significance. Hum Pathol. 2013;44:1508–15.PubMedCentralCrossRefPubMed
14.
Wei Q, Yan J, Fu B, Liu J, Zhong L, Yang Q, et al. IMP3 expression is associated with poor survival in cervical squamous cell carcinoma. Hum Pathol. 2014;45:2218–24.CrossRefPubMed
15.
Noske A, Faggad A, Wirtz R, Darb-Esfahani S, Sehouli J, Sinn B, et al. IMP3 expression in human ovarian cancer is associated with improved survival. Int J Gynecol Pathol. 2009;28:203–10.CrossRefPubMed
16.
Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014;133:401–4.CrossRefPubMed
17.
DeLair D, Oliva E, Kobel M, Macias A, Gilks CB, Soslow RA. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg Pathol. 2011;35:36–44.CrossRefPubMed
18.
Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A. IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol. 2009;40:1528–33.CrossRefPubMed
19.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.CrossRefPubMed
20.
Behbakht K, Randall TC, Benjamin I, Morgan MA, King S, Rubin SC. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol. 1998;70:255–8.CrossRefPubMed
21.
Pather S, Quinn MA. Clear-cell cancer of the ovary-is it chemosensitive? Int J Gynecol Cancer. 2005;15:432–7.CrossRefPubMed
22.
Takano M, Kikuchi Y, Yaegashi N, Kuzuya K, Ueki M, Tsuda H, et al. Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer. 2006;94:1369–74.PubMedCentralCrossRefPubMed
23.
Jenison EL, Montag AG, Griffiths CT, Welch WR, Lavin PT, Greer J, et al. Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma. Gynecol Oncol. 1989;32:65–71.CrossRefPubMed
24.
Kobel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010;29:203–11.CrossRefPubMed
25.
Ma SK, Zhang HT, Wu LY, Liu LY. Prognostic analysis of 88 patients with ovarian clear cell carcinoma. Zhonghua Zhong Liu Za Zhi. 2007;29:784–8.PubMed
26.
Ye S, You Y, Yang J, Cao D, Bai H, Huang H, et al. Comparison of pure and mixed-type clear cell carcinoma of the ovary: a clinicopathological analysis of 341 Chinese patients. Int J Gynecol Cancer. 2014;24:1590–6.CrossRefPubMed
27.
Higashi M, Kajiyama H, Shibata K, Mizuno M, Mizuno K, Hosono S, et al. Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types. Gynecol Oncol. 2011;123:474–8.CrossRefPubMed
28.
Mizuno M, Kikkawa F, Shibata K, Kajiyama H, Suzuki T, Ino K, et al. Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture. Oncology. 2003;65:29–36.CrossRefPubMed
29.
Hoskins PJ, Le N, Gilks B, Tinker A, Santos J, Wong F, et al. Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. J Clin Oncol. 2012;30:1656–62.CrossRefPubMed
30.
Rauh-Hain JA, Winograd D, Growdon WB, Schorge JO, Goodman AK, Boruta DM, et al. Prognostic determinants in patients with uterine and ovarian clear carcinoma. Gynecol Oncol. 2012;125:376–80.CrossRefPubMed
31.
Bennett JA, Dong F, Young RH, Oliva E. Clear cell carcinomas of the ovary. Evaluation of prognostic parameters based on a clinicopathologic analysis of 100 cases. Histopathology. 2015;66:808–15.CrossRefPubMed
32.
Scarfone G, Bergamini A, Noli S, Villa A, Cipriani S, Taccagni G, et al. Characteristics of clear cell ovarian cancer arising from endometriosis: a two center cohort study. Gynecol Oncol. 2014;133:480–4.CrossRefPubMed
33.
Davis M, Rauh-Hain JA, Andrade C, Boruta 2nd DM, Schorge JO, Horowitz NS, et al. Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary. Gynecol Oncol. 2014;132:760–6.CrossRefPubMed
34.
Orezzoli JP, Russell AH, Oliva E, Del Carmen MG, Eichhorn J, Fuller AF. Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol. 2008;110:336–44.CrossRefPubMed
35.
Slipicevic A, Oy GF, Askildt IC, Holth A, Hellesylt E, Florenes VA, et al. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. Hum Pathol. 2009;40:527–37.CrossRefPubMed
36.
Takada T, Iwase H, Iitsuka C, Nomura H, Sakamoto K, Omatsu K, et al. Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients. Int J Gynecol Cancer. 2012;22:573–8.CrossRefPubMed
37.
Mizuno M, Kajiyama H, Shibata K, Mizuno K, Yamamuro O, Kawai M, et al. Adjuvant chemotherapy for stage i ovarian clear cell carcinoma: is it necessary for stage IA? Int J Gynecol Cancer. 2012;22:1143–9.CrossRefPubMed
38.
Lu D, Yang X, Jiang NY, Woda BA, Liu Q, Dresser K, et al. IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer. Am J Surg Pathol. 2011;35:1638–45.CrossRefPubMed
39.
Samanta S, Sharma VM, Khan A, Mercurio AM. Regulation of IMP3 by EGFR signaling and repression by ERbeta: implications for triple-negative breast cancer. Oncogene. 2012;31:4689–97.PubMedCentralCrossRefPubMed
40.
Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M, Wu M, et al. Integrative genome comparison of primary and metastatic melanomas. PLoS One. 2010;5:e10770.PubMedCentralCrossRefPubMed
41.
Pei X, Li M, Zhan J, Yu Y, Wei X, Guan L, et al. Enhanced IMP3 Expression Activates NF-κB Pathway and Promotes Renal Cell Carcinoma Progression. PLoS One. 2015;10:e0124338.PubMedCentralCrossRefPubMed
42.
Hsu KF, Shen MR, Huang YF, Cheng YM, Lin SH, Chow NH, et al. Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer. Br J Cancer. 2015;113:414–24.CrossRefPubMed
Metadata
Title
Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression
Authors
Rui Bi
Xuxia Shen
Weiwei Zhang
Yufan Cheng
Zheng Feng
Xu Cai
Wentao Yang
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2016
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-016-0467-5

Other articles of this Issue 1/2016

Diagnostic Pathology 1/2016 Go to the issue

Case Report

Angiomatous pleomorphic xanthoastrocytoma: a case report and literature review

Case Report

Intrahepatic peribiliary perivascular epithelioid cell tumor (PEComa) associated with heterotopic pancreas: A case report

Methodology

BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay

Case Report

A fatal case of severe neck abscess due to a third branchial cleft fistula: morphologic and immunohistochemical analyses

Case Report

Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma

Research

Usefulness of pT1 substaging in papillary urothelial bladder carcinoma